Holen Sie sich die Stockscreener-App
139.89
1.40%
-0.4397
Schlusskurs vom Vortag:
$140.33
Offen:
$140.295
24-Stunden-Volumen:
1.31M
Relative Volume:
0.09
Marktkapitalisierung:
$55.79B
Einnahmen:
$2.23B
Nettoeinkommen (Verlust:
$-3.19B
KGV:
-17.17
EPS:
-8.1462
Netto-Cashflow:
$-1.60B
1W Leistung:
-8.25%
1M Leistung:
+133.85%
6M Leistung:
+148.24%
1J Leistung:
+465.47%
1-Tages-Spanne:
$136.70
$143.94
1-Wochen-Bereich:
$136.70
$154.69
52-Wochen-Spanne:
$22.28
$176.66
Moderna Inc Stock (MRNA) Company Profile
Firmenname
Moderna Inc
Sektor
Branche
Telefon
(617) 714-6500
Adresse
325 BINNEY STREET, CAMBRIDGE
Compare MRNA vs VRTX, REGN, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
139.74 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
VRTX
Vertex Pharmaceuticals Inc
|
525.08 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
804.12 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,000.43 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
209.10 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-28 | Fortgesetzt | Barclays | Equal Weight |
| 2026-01-07 | Fortgesetzt | UBS | Neutral |
| 2025-12-12 | Eingeleitet | Jefferies | Hold |
| 2025-03-13 | Eingeleitet | Citigroup | Neutral |
| 2025-02-18 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-01-29 | Herabstufung | Goldman | Buy → Neutral |
| 2024-12-18 | Herabstufung | Argus | Buy → Hold |
| 2024-12-10 | Fortgesetzt | BofA Securities | Underperform |
| 2024-11-19 | Eingeleitet | Berenberg | Hold |
| 2024-11-18 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Underperform |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-09-13 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2024-09-13 | Herabstufung | Jefferies | Buy → Hold |
| 2024-09-13 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-08-28 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2024-08-07 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2024-08-05 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | Herabstufung | HSBC Securities | Hold → Reduce |
| 2024-01-02 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2023-11-29 | Eingeleitet | Canaccord Genuity | Hold |
| 2023-11-03 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2023-11-02 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2023-08-04 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2023-07-24 | Eingeleitet | William Blair | Mkt Perform |
| 2023-07-14 | Eingeleitet | HSBC Securities | Reduce |
| 2023-06-26 | Hochstufung | UBS | Neutral → Buy |
| 2023-04-26 | Eingeleitet | Guggenheim | Neutral |
| 2023-03-13 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-02-24 | Herabstufung | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | Hochstufung | Jefferies | Hold → Buy |
| 2022-12-14 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | Hochstufung | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2022-02-01 | Hochstufung | Redburn | Sell → Neutral |
| 2022-01-26 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2022-01-21 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-01-21 | Eingeleitet | UBS | Neutral |
| 2021-12-07 | Eingeleitet | Cowen | Market Perform |
| 2021-11-09 | Eingeleitet | Wolfe Research | Outperform |
| 2021-10-22 | Eingeleitet | Deutsche Bank | Sell |
| 2021-10-15 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2021-08-06 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | Bestätigt | Jefferies | Hold |
| 2021-02-01 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-12-16 | Herabstufung | Jefferies | Buy → Hold |
| 2020-12-16 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | Herabstufung | Needham | Buy → Hold |
| 2020-11-23 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-11-17 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | Herabstufung | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2020-07-20 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-07-13 | Eingeleitet | Jefferies | Buy |
| 2020-06-30 | Eingeleitet | Argus | Buy |
| 2020-06-08 | Eingeleitet | Barclays | Overweight |
| 2020-04-30 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-03-05 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-10-25 | Eingeleitet | ROTH Capital | Buy |
| 2019-04-05 | Eingeleitet | Chardan Capital Markets | Buy |
Alle ansehen
Moderna Inc Aktie (MRNA) Neueste Nachrichten
Moderna stock heads into the open after a 1.8 percent drop - AD HOC NEWS
Discipline and Rules-Based Execution in MRNA Response - Stock Traders Daily
Moderna (NASDAQ: MRNA) withholds 5,704 shares for legal chief’s RSU taxes - Stock Titan
Moderna (NASDAQ: MRNA) CFO now holds 106,179 unvested RSUs - Stock Titan
What to know about a first-of-its kind flu shot for people over 50 - NBC 5 Chicago
Merck and Moderna Announce Positive Phase 3 Results for Intismeran Autogene Plus Pembrolizumab in High-Risk MelanomaThe Babak Lab - Oncodaily
MRNA Stock Soars 143% in a Month: Time to Buy, Hold or Sell? - Yahoo Finance
Merck Trading Near 52-Week High: Is the Stock a Buy, Hold or Sell? - The Globe and Mail
Merck Trading Near 52-Week High: Is the Stock a Buy, Hold or Sell? - Zacks Investment Research
Moderna Inc. stock gains sharply as cancer vaccine data lifts valuation - AD HOC NEWS
Nykredit A S Invests $913,000 in Moderna, Inc. $MRNA - MarketBeat
Moderna Inc. stock gains strongly as cancer vaccine partnership fuels rally - AD HOC NEWS
Moderna Stock (MRNA) Opinions on Melanoma Vaccine Trial Results - Quiver Quantitative
How Is Moderna's Stock Performance Compared to Other Healthcare Stocks - Yahoo Finance
Moderna, Inc. (MRNA) Stock Analysis: Is the Biotech Giant’s Market Cap Justified Amid a 19.96% Potential Downside? - DirectorsTalk Interviews
Alibaba DAMO Academy's Liver Cancer AI Model Tops Nature Medicine; Clinical Trial Catches 15 Missed Diagnoses - finance.biggo.com
Moderna Expands mRNA Territory Beyond Personalized Cancer Vaccines to Universal Shots and In Vivo CAR-T - finance.biggo.com
Moderna Moves Beyond Personalized Cancer Vaccines to Universal Shot - Seoul Economic Daily
Moderna Inc. stock holds steady as investors watch vaccine revenue and oncology pipeline - AD HOC NEWS
MRNA Looks 503.7% Overvalued on GF Value™ - GuruFocus
Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It - MarketBeat
If You'd Invested in Moderna (MRNA) Stock 5 Years Ago, Here's How Much You'd Have Today (Hint: You'd Be Disappointed -- But Not If You Bought It 1 Year Ago.) - Yahoo Finance
AlphaGrep UK Ltd Invests $568,000 in Moderna, Inc. $MRNA - MarketBeat
Moderna begins Phase 1 clinical trial of Ebola vaccine against strain behind DRC outbreakABC News - ABC News - Breaking News, Latest News and Videos
Promising Biotech Stocks Worth WatchingSeptember 5th - MarketBeat
MRNA Looks 503.4% Overvalued on GF Value™ - GuruFocus
Healthcare August recap: Moderna jumps 156% as biotech shines; DaVita sinks - Seeking Alpha
Personalized Cancer Vaccine Breakthrough Ignites Sequencing Sector, Tempus AI's Personalis Bid Faces Rivalry Speculation - finance.biggo.com
Step Capital Management Pte. Ltd. Has $48.67 Million Stake in Moderna, Inc. $MRNA - MarketBeat
22,477 Shares in Moderna, Inc. $MRNA Acquired by AXQ Capital LP - MarketBeat
The Cancer Vaccine Gold Rush Has Begun. So Has the Race for Picks and Shovels. - WSJ
What Does Moderna (MRNA) Bird Flu Phase 3 Trial Mean For Its Growth? - Yahoo Finance
Is Moderna (MRNA) Fully Valued After Its New 2032 Convertible Notes? - Yahoo Finance
Moderna's mRNA flu vaccine, mFlusiva, offers option for adults 50-64 with potential benefits over traditional shot - ABC7 New York
Moderna (MRNA) Stock Looks Expensive On Sales After A Very Large Run - Yahoo Finance
Wall Street Has Cooled on Moderna After Its Stock Jumped Over 5X. But Does the mRNA Leader Have More Room to Run? - Yahoo Finance
Healthcare Stocks To Watch TodaySeptember 4th - MarketBeat
Moderna stock falls after Rothschild Redburn downgrade - AD HOC NEWS
GSK's mRNA flu vaccine data closely tracks Moderna's, Deutsche Bank says - Yahoo! Finance Canada
Moderna Inc (MRNA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Why Moderna (MRNA) Stock Is Down Today - Yahoo Finance
Moderna is now overvalued after cancer vaccine-led stock surge, Rothschild & Co. says - CNBC TV18
BioNTech vs. Moderna: Which Is the Better Cancer Vaccine Stock to Buy Now? - The Globe and Mail
Moderna (MRNA) Price Forecast: Bullish Pennant Points Toward Higher Targets - FXEmpire
Moderna (NASDAQ:MRNA) Insider Sells $485,766.45 in Stock - MarketBeat
Moderna (MRNA) CFO has 2,475 stock units vest in Sept. award - Stock Titan
Moderna (MRNA) legal chief trades stock under 10b5-1 plan - Stock Titan
MRNA Looks 500.3% Overvalued on GF Value™ - GuruFocus
Can Moderna reclaim 52-week highs after pullback, or have best levels been seen? - Investing.com
Why Moderna's Cancer Vaccine Matters To Investors - Seeking Alpha
Moderna stock slips as Rothschild downgrades (MRNA:NASDAQ) - Seeking Alpha
Finanzdaten der Moderna Inc-Aktie (MRNA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):